Projet SECRET (Horizon 2020, appel à projets 2019)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : SIGNED

Breast and colorectal cancer (BC and CRC) are the most frequent cancers accounting for 19% of all deaths from cancer in Europe. In case of triple-negative BC (TNBC) targeted therapies are not available and non-selective chemotherapy is the only treatment option. Targeted therapy has been approved for the treatment of advanced CRC, but response rates are low and treatment is limited to a subgroup of patients. Also, TNBC and CRC patients are prone to develop metastases and have a poor prognosis underpinning the need for new targeted and broadly applicable therapeutic strategies. Tumor cell secretion contributes to hallmarks of cancer e.g. hyperproliferation, evasion of growth suppression, loss of cell polarity, activation of cell motility, invasion and metastasis, shaping of the tumor microenvironment through altered presentation of proteins and the secretome, and resistance to cell death. Dysregulated secretion is thus a driver of cancer progression and therefore holds promise as a general therapeutic target for the treatment of cancers. However, strategies to exploit the secretory pathway for therapeutic and diagnostic purposes are still in their infancy due to the incomplete understanding of how this pathway is regulated by aberrant signaling. The overall research objective of SECRET is to drive the understanding of the mutual regulation of the secretory pathway and signaling in cancer, which will serve as a platform to identify and interrogate novel diagnostic and therapeutic strategies. SECRET comprises 11 beneficiaries and 7 partner organizations from 9 countries. Coordinated by the University of Stuttgart, SECRET will train 15 talented ESRs in the field of translational cancer systems cell biology and systems medicine towards a career in industry or academia through a highly interdisciplinary and intersectoral research training programme and inspire them to exploit the SECRETory pathway as a treasure trove to design novel therapeutic strategies against cancer.

Mots clés : membrane trafficking, secretome, solid cancers, tumor microenvironment, cancer systems, medicine, biomarkers, targeted cancer therapy

Participants :
- Innsbruck Medical University (Autriche) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 370624.05 €
- Medical University of Vienna (Autriche) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 264207.24 €
- Anaxomics (Spain) (Espagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 250904.88 €
- University of Stuttgart (Allemagne) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 758365.2 €
- Charles river discovery research services germany gmbh (Allemagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 252788.4 €
- National Research Council (Italie) — Partner, beneficiary, Recherche, subvention : 261499.68 €
- University of Oslo (Norvège) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 174593.33 €
- Oslo University Hospital (Norvège) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 292342.32 €
- Amsterdam University Medical Centers (Pays-Bas) — Partner, beneficiary, Recherche, subvention : 531239.76 €
- University of Freiburg (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 252788.4 €
- Tel Aviv University (Israël) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 263500.92 €
- Protatouans - etaireia ereynas viotechnologias monoprosopi etaireia periorismenis eythinis (Grèce) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 243017.64 €